SCHEMBL5515360

SCHEMBL5515360

NS(=O)(=O)CCCc1ccncc1

nearest known ligand 0.66

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HRH1 P35367 2/20 0.52
NPC1 O15118 1/20 0.50
KMT2A Q03164 1/20 0.50
CA2 P00918 4/20 0.49
LOXL2 Q9Y4K0 2/20 0.48
RECQL P46063 1/20 0.46
LMNA P02545 2/20 0.43
HTT P42858 2/20 0.43
SMN1; SMN2 Q16637 2/20 0.43
TSHR P16473 1/20 0.43
RAB9A P51151 1/20 0.42
ALDH1A1 P00352 1/20 0.41
TDP1 Q9NUW8 1/20 0.41
CA1 P00915 2/20 0.41
CA5A P35218 1/20 0.41
CA7 P43166 1/20 0.41
CA5B Q9Y2D0 1/20 0.41
HRH4 Q9H3N8 1/20 0.41
HRH3 Q9Y5N1 1/20 0.41
NAAA Q02083 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4250874 0.88 RECQL (0.59) HRH1NPC1KMT2ACA2LOXL2
SCHEMBL1903867 0.80 KMT2A (0.54) HRH1NPC1KMT2ALOXL2LMNA
SCHEMBL10917591 0.80 NPC1 (0.50) HRH1NPC1KMT2ALOXL2LMNA
SCHEMBL1793990 0.79 CA2 (0.72) CA2RECQLTSHRCA1CA5A
SCHEMBL24670084 0.78 CA2 (0.52) CA2LOXL2RECQLSMN1; SMN2CA1
SCHEMBL4061411 0.78 CA2 (0.70) CA2RECQLTSHRCA1CA5A
SCHEMBL7670239 0.76 RECQL (0.50) CA2RECQLSMN1; SMN2CA1CA7
SCHEMBL660034 0.76 RECQL (0.50) NPC1KMT2ACA2RECQLSMN1; SMN2
SCHEMBL24668668 0.75 LOX (0.51) CA2LOXL2RECQL
SCHEMBL351920 0.75 HRH1 (0.65) HRH1NPC1KMT2ALOXL2LMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7223755-B2 Hydroxymorpholinone derivative and medicinal use thereof SENJU PHARMACEUTICAL CO., LTD. (JP) 2007-05-29 US disclosed
US-20050176704-A1 Hydroxymorpholinone derivative and medicinal use thereof SENJU PHARMACEUTICAL CO., LTD. (JP) 2005-08-11 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050176704-A1 Hydroxymorpholinone derivative and medicinal use thereof CAPN1, OPRM1, CAPN2 HRH1 431/4885NPC1 1705/4885KMT2A 3923/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.